Evidence map›Paper›PMID 29637406›Full record

ReviewCurrent rheumatology reports2018

Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis.

Silvia Rosina, Giulia Camilla Varnier, Marta Mazzoni, Stefano Lanni, Clara Malattia, Angelo Ravelli

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Treat-to-Target in Pediatric Rheumatic Diseases.Current rheumatology reports · 2023
    Review
  3. Outcome Scores in Pediatric Rheumatology.Current rheumatology reports · 2021
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Silvia RosinaUniversità degli Studi di Genova, Genoa, Italy.
Giulia Camilla VarnierUniversità degli Studi di Genova, Genoa, Italy.
Marta MazzoniUniversità degli Studi di Genova, Genoa, Italy.
Stefano LanniClinica Pediatrica e Reumatologia, Istituto Giannina Gaslini, Via G. Gaslini 5, 16147, Genoa, Italy.
Clara MalattiaUniversità degli Studi di Genova, Genoa, Italy.
Angelo RavelliUniversità degli Studi di Genova, Genoa, Italy. angeloravelli@gaslini.org.
University of Genoa · ITIstituto Giannina Gaslini · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis paper aims to provide a summary of the recent therapeutic advances and the latest research on outcome measures for clinical trials in juvenile dermatomyositis (JDM). RECENT

findingsRecent randomized controlled trials (RCTs) have demonstrated the superiority of the combination of prednisone with methotrexate over other conventional therapies and the potential effectiveness of rituximab in refractory cases. A multinational project has led to develop new criteria for the definition of minimal, moderate, and major improvement in future JDM clinical trials. This effort has been paralleled by the establishment of criteria for clinically inactive disease. The validation of the first composite disease activity score for JDM is in progress. The new outcome measures will increase the reliability of assessment of clinical response in JDM clinical trials and foster future multinational RCTs aimed to investigate novel treatment strategies for refractory forms of JDM.

Indexed as

DermatomyositisGlucocorticoidsHumansImmunologic FactorsRandomized Controlled Trials as TopicResearch DesignRituximabSeverity of Illness IndexTreatment OutcomeGlucocorticoidsImmunologic FactorsRituximabDisease remissionIdiopathic inflammatory myopathiesJuvenile dermatomyositisOutcome measuresRandomized clinical trials

Identifiers

PMID29637406
OpenAlexW2797016220

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.